Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cellular Goods is a UK public company that originally launched as a biosynthetic cannabinoid consumer wellness business focused on premium skincare and topical recovery products. Its early commercial products used lab-made cannabinoids such as cannabidiol and cannabigerol in topical formulations positioned around anti-inflammatory, skin-calming, and age-prevention benefits. In 2024, the company shifted strategy and now presents itself as Cel AI PLC, focused on AI-powered personalized beauty advice and product recommendations while still operating the Cellular Goods skincare brand. The business is listed on the Main Market of the London Stock Exchange and remains headquartered in London. For a biotech analyst, it is best characterized as a public consumer wellness/beauty technology company rather than a drug-development biotech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cellular Goods.